stockrowOSR Health, Inc.
OSRH Healthcare Biotechnology
OSR Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 million, down 17.7% from fiscal 2024.
- Revenue
- −72.2%
- EPS
- −200.0%
- Free cash flow
- −398.8%
- Total debt
- +28.2%
Quarter to June 2026, against a year earlier
Follow OSRH
Alert me
OSR Health, Inc. (OSRH) EV/Sales
As of 6 November 2026, OSR Health, Inc. (OSRH) trades at a EV/Sales of 4.9×. Over the past ten years it has ranged from 0.0× (December 2024) to 12.9× (August 2026); the current reading is higher than 66% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.0× | (21.05%) |
| FY2024 | 7.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 8.0× | (4.81%) |
| Mar 2026 | 8.4× | 40.05% |
| Dec 2025 | 6.0× | 48.46% |
| Sep 2025 | 4.0× | (38.37%) |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CELZ Creative Medical Technology Holdings, Inc. compare | −378× |
| AZTR Azitra, Inc. compare | −9.1× |
| XBIO Xenetic Biosciences, Inc. compare | −0.3× |
| DRMA Dermata Therapeutics, Inc. compare | n/m |
| NCNA NuCana PLC Sponsored ADR compare | n/m |
| PMCB Nuvilex Inc. compare | n/m |
| SKYE Skye Bioscience, Inc. compare | 3.6× |
| OSRH OSR Health, Inc. | 4.9× |
| ADTX Aditxt, Inc. compare | 73.3× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)